Advisor Group Holdings, Inc. Inhibrx, Inc. Transaction History

Advisor Group Holdings, Inc.

$40.6 Billion
Q2 2024

A detailed history of Advisor Group Holdings, Inc. transactions in Inhibrx, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 6,690 shares of INBX stock, worth $107,240. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,690

Previous 7,227 7.43%

Holding current value

$107,240

Previous $252,000 62.7%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$14.06 - $35.08 $7,550 - $18,837	-537 Reduced 7.43%	6,690 $94,000
Q1 2024 May 10, 2024	SELL	$32.76 - $39.56 $12,710 - $15,349	-388 Reduced 5.1%	7,227 $252,000
Q4 2023 Feb 12, 2024	SELL	$14.5 - $38.0 $110,852 - $290,510	-7,645 Reduced 50.1%	7,615 $289,000
Q3 2023 Nov 13, 2023	BUY	$15.75 - $26.31 $113,085 - $188,905	7,180 Added 88.86%	15,260 $280,000
Q2 2023 Aug 10, 2023	SELL	$16.96 - $27.82 $4,833 - $7,928	-285 Reduced 3.41%	8,080 $209,000
Q4 2022 Feb 10, 2023	SELL	$20.18 - $33.33 $9,686 - $15,998	-480 Reduced 5.43%	8,365 $206,000
Q3 2022 Nov 14, 2022	SELL	$11.58 - $24.73 $2,316 - $4,946	-200 Reduced 2.21%	8,845 $159,000
Q2 2022 Aug 10, 2022	SELL	$8.52 - $25.26 $4,473 - $13,261	-525 Reduced 5.49%	9,045 $102,000
Q1 2022 May 04, 2022	SELL	$19.89 - $43.18 $21,879 - $47,498	-1,100 Reduced 10.31%	9,570 $213,000
Q2 2021 Aug 02, 2021	BUY	$14.69 - $27.52 $102,389 - $191,814	6,970 Added 188.38%	10,670 $294,000
Q1 2021 May 13, 2021	BUY	$16.27 - $41.26 $29,286 - $74,268	1,800 Added 94.74%	3,700 $74,000
Q3 2020 Nov 12, 2020	BUY	$16.77 - $20.65 $31,863 - $39,235	1,900 New	1,900 $34,000

Others Institutions Holding INBX

# of Institutions

Shares Held

25.3K

Call Options Held

Put Options Held

Credit Suisse Ag Zurich, V8

18.6K
Shares

$297,532
0.0% of portfolio

View Full List

About Inhibrx, Inc.

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $626M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

More about INBX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.

Account

Advisor Group Holdings, Inc. Inhibrx, Inc. Transaction History